Loading page
Loading page
Loading substance route
Documentation indicates only a threshold range of approximately 100-200 ug. Extremely limited human data exists for this compound. Insufficient evidence to establish intermediate dose tiers. Avoid redosing due to unknown safety profile.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
2C-B-FLY-NBOMe was discovered in 2002 and subsequently researched by Ralf Heim at the Free University of Berlin. The compound was later investigated in greater detail by a research team at Purdue University led by pharmacologist David E. Nichols. Structurally, the substance represents a hybrid design that combines the rigid benzodifuran ring system characteristic of the FLY series with the N-benzyl substitution pattern found in NBOMe compounds.
Controlled under the Misuse of Drugs Act 1971 through the N-benzylphenethylamine catch-all clause, which encompasses N-benzyl substituted phenethylamine derivatives. Class A substances carry the most severe penalties under UK law.
Designated as a controlled substance in the state of Vermont since January 2016. State-level scheduling; federal status may vary.
10 sources cited
